Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
Go back to Seattle Genetics Reports Fourth Quarter and Year 2017 Financial Results
February 7, 2018 7:24 AM EST
H.C. Wainwright raised its price target on Seattle Genetics (NASDAQ: SGEN) to $77.00 (from $75.00) while maintaining a Buy rating.
Analyst Andrew Fein commented, "Beyond ADCETRISs continuous label expansion/revenue growth and the companys ADC platform milestone generation, we see the solid tumor pipeline as the most interesting value driver with three late-stage programs that could expand SGENs footprint beyond hematology. The recent acquisition of Cascadian Therapeutics (CASC; not rated) and its HER2+ breast cancer... More
February 7, 2018 7:10 AM EST
SunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $60.00 (from $52.00) while maintaining a Hold rating.
Analyst Suneja Yatin commented, "SGEN reported a slight (+3%) beat in Adcetris 4Q sales, while LPS also topped Street (-$0.41 vs. -$0.45E) on... More
